CICC: Maintains "outperform industry" rating on Rongchang Bio (09995.HK) and raises target price to HK$45.

According to the Wise Finance APP, Zhongjin released a research report stating that it basically maintains its forecast for the net loss of Rongchang Biotech (09995.HK) in 2025/2026 at 915 million yuan/333 million yuan. Due to the data of tiotropium MG exceeding the bank's expectations, it is expected to open up the global market space for this indication. Based on the DCF model, the bank maintains an outperform rating on the company, raising the target price by 40.6% to 45 Hong Kong dollars, representing a 21.8% upside from the current stock price.